Previous Close | 1.78 |
1-Year Change | 37.98% |
6-Months Change | -14.42% |
3-Months Change | -22.27% |
Moving Avg (50d) | 2.0462 |
Moving Avg (200d) | 2.2595 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 199.1M |
Beta (3-Years) | 0.9 |
Revenue Growth (ttm) | 42.8% |
Net Profit Margin (ttm) | -202.51% |
Return On Assets (ttm) | -94.16% |
EPS (ttm) | -2.36 |
PE Ratio (ttm) | -0.75 |
Dividend Yield | % |
Asset Description: | Esperion Therapeutics, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-13 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
1.744 | 1.691 | 1.655 | 1.602 | 1.513 | 1.424 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.